ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). This feature is in beta and may change with future updates. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. ITI-1001 is an alternative, cell-free approach to treating GBM. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. HLB also secured an option to make further investment into the company in the months ahead. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). In addition, ITI-1001 represents a far more cost-effective approach. Share this article. Description. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. For more information, please visit www.immunomix.com. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. Coordinates: 245831.9N 1213154.0E. 2016;2016:4857869. 858-366-3243, Internet Explorer presents a security risk. January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. ITI Media: Phone Number +119196161923. ITI Company: Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. These factors are currently under intense focus in the cancer immunotherapy landscape. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Pays for all health and welfare insurance premiums 100%. Nature. Melody Carey We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. You will receive a reply to confirm the receipt of your application. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. View detailed 028300.KR description & address. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. amy@juniper-point.com Katie Pearce. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. J Immunol. Please include the Job Code in the subject line and attach a cover letter and salary requirement along with a current resume to complete your candidacy submission for each position in which you are interested. Active, Closed, Last funding round type (e.g. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. To explore Immunic Therapeutics's full profile, request access. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). ITI-3000 Merkel Cell Carcinoma - pDNA. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. mcarey@rxir.com all maps fatal bullet; who is running for senate in maryland 2022 Last Funding Type Venture - Series Unknown. ITI-2000 HPV+ Tumors. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). Founded Date 2015. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . ITI maintains its headquarters in Rockville, Maryland. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. Handled COVID very well. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Jan 2006 - Present17 years 2 months. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. Animal Health All. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . All content is posted anonymously by employees working at Immunomic Therapeutics. This is the Immunomic Therapeutics company profile. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. 301-968-3501 Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Headquarters Location. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Operating Status Active. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. 28 Employees . Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. 438 followers 429 connections. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Animal Health All. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. CONTACT US. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. 15010 Broschart Road Suite 250. ITI-ID Candidate Multiple infectious diseases. aanagnostou@immunomix.com Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. mkemp@immunomix.com UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Curr Opin Immunol. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. ITI-1000 GBM - Cell Therapy. Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies.